Biotech · Private company · Philadelphia, PA, US
BriaCell Therapeutics Corporation
Track this companyFree. Adds BriaCell Therapeutics Corporation to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- CyclophosphamidePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Interferon infiltration of the inoculation sitePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RetifanlimabPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SV-BR-1-GMPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Treatment of Physician's ChoicePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BC1 cell linePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Bria-OTS regimen and CPI (tislelizumab)Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Bria-OTS regimen and CPI (tislelizumab) expansion cohortPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · BreastcancerClinicalTrials.gov · fetched Nov 12, 2026
- Interferon InoculationPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Interferon-alpha-2bPhase 2 · BreastcancerClinicalTrials.gov · fetched Nov 12, 2026
- Low dose cyclophosphamidePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SV-BR-1-GMPhase 2 · BreastcancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerPHASE1_PHASE2 · UNKNOWN · started May 29, 2024ClinicalTrials.gov NCT06471673 · fetched Nov 12, 2026
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.PHASE3 · RECRUITING · started Dec 5, 2023ClinicalTrials.gov NCT06072612 · fetched Nov 12, 2026
- Combination Study of SV-BR-1-GM With RetifanlimabPHASE1_PHASE2 · COMPLETED · started Mar 16, 2018ClinicalTrials.gov NCT03328026 · fetched Nov 12, 2026
- SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerPHASE1_PHASE2 · COMPLETED · started May 5, 2017ClinicalTrials.gov NCT03066947 · fetched Nov 12, 2026
NIH awards2
- An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.Fiscal year 2026 · $947.9KNIH RePORTER 5R44CA281555-03 · fetched Nov 12, 2026
- An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.Fiscal year 2025 · $1.1MNIH RePORTER 2R44CA281555-02 · fetched Nov 12, 2026